2. Protein Tyrosine Kinase/RTK Antibody-Drug Conjugate/ADC Related
  3. FGFR Radionuclide-Drug Conjugates (RDCs)
  4. cRY9M

cRY9M is a cyclic peptide that binds to FGFR1, with a KD value of 58 nM. cRY9M binds specifically to FGFR1, exhibits enhanced in vivo stability, and shows extremely low degradation in blood, urine and liver homogenate after injection. cRY9M displays significant specific uptake in FGFR1-positive tumor xenograft models, while its uptake decreases in FGFR1-negative tumor models and blocking models. The NOTA-chelated precursor of cRY9M can be labeled with 68Ga to obtain [68Ga]Ga-NOTA-cRY9M, which is used for research on non-invasive imaging of FGFR1 expression in non-small cell lung cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

cRY9M

cRY9M Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

cRY9M Related Antibodies

Top Publications Citing Use of Products

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

cRY9M is a cyclic peptide that binds to FGFR1, with a KD value of 58 nM. cRY9M binds specifically to FGFR1, exhibits enhanced in vivo stability, and shows extremely low degradation in blood, urine and liver homogenate after injection. cRY9M displays significant specific uptake in FGFR1-positive tumor xenograft models, while its uptake decreases in FGFR1-negative tumor models and blocking models. The NOTA-chelated precursor of cRY9M can be labeled with 68Ga to obtain [68Ga]Ga-NOTA-cRY9M, which is used for research on non-invasive imaging of FGFR1 expression in non-small cell lung cancer[1].

In Vitro

[68Ga]Ga-NOTA-cRY9M (4 h) retains a radiochemical purity of over 95% after incubation in fetal bovine serum (FBS) at 37 °C for 4 hours[1].
[68Ga]Ga-NOTA-cRY9M (74 kBq; 15-120 min) exhibits time-dependent and FGFR1-specific cellular uptake in Calu-3, NCI-H520 and NCI-H2170 cells[1].
[68Ga]Ga-NOTA-cRY9M (74 kBq; 2 h) inhibits the binding of FGFR1 to Calu-3 cells, with an IC50 of 62 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

cRY9M Related Antibodies
In Vivo

[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) exhibits superior tumor targeting in FGFR1-overexpressing NSCLC xenograft models, with a peak tumor uptake of 3.69 %ID/g and a maximum tumor-to-muscle ratio of 5.56[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) targets NSCLC xenografts with moderate FGFR1 expression, reaching a peak tumor uptake of 3.11 %ID/g and a maximum tumor-to-muscle ratio of 4.10[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) shows extremely low uptake in FGFR1-low-expressing NSCLC xenografts, with a maximum tumor uptake rate of 1.20 %ID/g and a low tumor-to-muscle ratio[1].
Pretreatment with NOTA-cRY9M (intravenous injection; single dose, 30 minutes in advance, 200-fold excess) blocks the FGFR1-specific uptake of [68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) in Calu-3 xenograft tumors, reducing the maximum tumor uptake to 1.45 %ID/g[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single administration) can specifically target NSCLC PDX tumors with high FGFR1 expression, reaching a peak tumor uptake of 3.84 %ID/g and a maximum tumor-to-muscle ratio of 5.28; pre-administration of an excess unlabeled peptide (200-fold excess; intravenous injection; single administration, 30 minutes in advance) blocks its uptake[1].
Uptake of [68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single administration) in NSCLC PDX tumors correlates with FGFR1 expression, showing moderate accumulation in PDX-M tumors[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) shows extremely low uptake in FGFR1-low-expressing NSCLC PDX tumors, which is consistent with the low target expression[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) can specifically target FGFR1-positive breast cancer xenografts, and its uptake level correlates with target expression[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single administration) specifically targets FGFR1-positive pancreatic cancer xenografts, with its accumulation level correlated with target expression[1].
[68Ga]Ga-NOTA-cRY9M (3.7 MBq; intravenous injection; single dose) shows extremely low uptake in FGFR1-low-expressing breast cancer xenografts, which is consistent with the low expression level of the target[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Achieved peak tumor uptake of 3.69 %ID/g at 10 minutes postinjection, with gradual decline to 3.33 %ID/g by 60 minutes.
Exhibited primarily renal excretion with low hepatic retention.
Reached a maximum tumor-to-muscle ratio of 5.56 at 60 minutes, with tumor-to-liver and tumor-to-lung ratios of approximately 2.3 and 3.3, respectively, at 60 minutes.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H520 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Achieved peak tumor uptake of 3.11 %ID/g at 10 minutes postinjection, with subsequent decline.
Reached a maximum tumor-to-muscle ratio of 4.10 at 60 minutes.
Showed tumor uptake of 2.61 %ID/g at 60 minutes postinjection via ex vivo biodistribution.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H2170 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Reached a maximum tumor uptake of 1.20 %ID/g.
Maintained a consistently low tumor-to-muscle ratio of ~1.42 throughout the imaging window.
Showed tumor uptake of 0.91 %ID/g at 60 minutes postinjection via ex vivo biodistribution.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks, blocking study with unlabeled NOTA-cRY9M)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M
Administration: i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer)
Result: Reduced maximal tumor accumulation to 1.45 %ID/g at 60 minutes postinjection.
Reached a tumor-to-muscle ratio of only 1.77 at 60 minutes.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-H, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M (blocking study)
Administration: i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer, blocking study)
Result: Achieved peak tumor uptake of 3.84 %ID/g at 10 minutes postinjection.
Reached a maximum tumor-to-muscle ratio of 5.28.
Reduced tumor uptake to 1.28 %ID/g after pretreatment with unlabeled NOTA-cRY9M.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-M, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited tumor uptake levels intermediate between PDX-H and PDX-L, with corresponding tumor-to-muscle ratios consistent with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-L, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited minimal tumor uptake, comparable to background levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-231 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed significant accumulation in MDA-MB-231 tumors (FGFR1-positive), correlating with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of PANC-1 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed significant accumulation in PANC-1 tumors (FGFR1-positive), correlating with FGFR1 expression levels.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-468 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Showed minimal accumulation in MDA-MB-468 tumors (FGFR1-low), correlating with low target expression.
Animal Model: BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of FGFR1-knockdown Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size)[1]
Dosage: 3.7 MBq [68Ga]Ga-NOTA-cRY9M
Administration: i.v.; single dose
Result: Exhibited substantial reduction in tracer uptake (1.10 %ID/g) in FGFR1-knockdown Calu-3 xenografts compared to control Calu-3 tumors (3.83 %ID/g).
Showed correspondingly lower tumor-to-muscle ratios (2.11 vs 5.89) in FGFR1-knockdown vs control tumors.
Molecular Weight

1312.48

Formula

C59H89N23O12
Sequence

Cyclo(Arg-Trp-Arg-Lys-Gln-Thr-Arg-His-Tyr)
Sequence Shortening

Cyclo(RWRKQTRHY)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

cRY9M Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

cRY9MFGFRRadionuclide-Drug Conjugates (RDCs)Fibroblast growth factor receptorPDX tumorsFGFR4FGFR3FGFR2NCI-H520NCI-H2170FGFR1NSCLC xenograft modelsCalu-3non-small cell lung cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
cRY9M
Cat. No.:
HY-P11853
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.